In a Nov. 9 story and headline about a Food and Drug Administration review of a drug being developed by XenoPort Inc. and GlaxoSmithKline PLC, The Associated Press reported erroneously on the nature of the FDA review. The FDA is considering an application for the drug in restless legs syndrome, not neuropathic pain.
7 Simple Steps to Eliminate School Shootings Overnight
Israel Figured Out How to Prevent School Shootings 40 Years Ago-It's Time the US Followed Suit
The Angry Liberal Mob